Proteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on Monday
Proteon Therapeutics, Inc. (NASDAQ:PRTO) is scheduled to announce its earnings results before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.11. On average, analysts expect Proteon Therapeutics to post $-1.54 EPS for the current fiscal year and $-1.64 EPS for the next fiscal year.
Shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) opened at 1.99 on Monday. The company’s market capitalization is $35.06 million. Proteon Therapeutics, Inc. has a 1-year low of $1.10 and a 1-year high of $11.45. The company’s 50 day moving average is $2.01 and its 200-day moving average is $1.54.
COPYRIGHT VIOLATION NOTICE: “Proteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on Monday” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/30/proteon-therapeutics-inc-prto-set-to-announce-quarterly-earnings-on-monday.html.
PRTO has been the subject of several analyst reports. Zacks Investment Research lowered shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a report on Wednesday, August 16th. HC Wainwright set a $2.00 price target on shares of Proteon Therapeutics and gave the stock a “hold” rating in a report on Wednesday, August 9th. Finally, Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, August 8th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $6.25.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.